Ursodeoxycholic acid - Santen Pharmaceutical

Alternative Names: STN 1013600

Latest Information Update: 01 Jul 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Santen Pharmaceutical
Class Cholic acids; Eye disorder therapies; Gallstone therapies; Hepatoprotectants; Small molecules
Mechanism of Action Cholesterol inhibitors; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Jul 2024 Discontinued - Phase-I for Presbyopia in Japan (Ophthalmic) prior to June 2024 (Santen Pharmaceutical Pipeline, June 2024)
01 Jul 2024 Discontinued - Phase-II for Presbyopia in USA (Ophthalmic) prior to June 2024 (Santen Pharmaceutical Pipeline, June 2024)
27 Jul 2023 Santen completes a phase II OPSIS trial in Presbyopia in USA (Ophthalmic) (NCT05665387)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com